Allergan Inc. (AGN): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Allergan ( AGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.7%. By the end of trading, Allergan rose $1.75 (1.6%) to $112.03 on average volume. Throughout the day, 1,658,674 shares of Allergan exchanged hands as compared to its average daily volume of 2,154,700 shares. The stock ranged in a price between $110.69-$112.16 after having opened the day at $110.75 as compared to the previous trading day's close of $110.28. Other companies within the Health Care sector that increased today were: BG Medicine ( BGMD), up 37.7%, LCA-Vision ( LCAV), up 18.0%, Pingtan Marine Enterprise ( PME), up 16.2% and Biostar Pharmaceuticals ( BSPM), up 15.3%.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $33.0 billion and is part of the drugs industry. Shares are down 0.7% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, increase in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Mast Therapeutics ( MSTX), down 31.8%, Chelsea Therapeutics International ( CHTP), down 14.6%, Inovio Pharmaceuticals ( INO), down 12.9% and ERBA Diagnostics ( ERB), down 10.8% , were all laggards within the health care sector with Celgene Corporation ( CELG) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Rules for When the Markets Go Wild: Cramer's 'Mad Money' Recap (Friday 2/23/18)

Rules for When the Markets Go Wild: Cramer's 'Mad Money' Recap (Friday 2/23/18)

24 Stocks Hedge Funds Are Loving Right Now

24 Stocks Hedge Funds Are Loving Right Now

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises